Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Eur Urol. 2023 Jun 29;84(3):331–340. doi: 10.1016/j.eururo.2023.05.031

Fig. 1 – Cumulative incidence of cause-specific failure types in composite endpoints. (A) MFS, (B) DFS, (C) EFS (PSA nadir+2 ng/ml), (D) PCSS.

Fig. 1 –

DFS = disease-free survival; EFS = event-free survival; MFS = metastasis-free survival; PCSS = prostate cancer-specific survival; PSA = prostate-specific antigen.